Yuxin Mu

8PUBLICATIONS
12CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 04, 2026
Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial.

|Jul 02, 2022
Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.

Yan Li, Ziyi Xu, Shouzheng Wang

|May 10, 2020
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.

Yuxin Mu, Xuezhi Hao, Puyuan Xing

|May 31, 2019
Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.

Hongge Liang, Xia Song, Yuhui Zhang

|May 25, 2019
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib.

Yuxin Mu, Xuezhi Hao, Ke Yang

|May 17, 2019
Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations.

Shouzheng Wang, Puyuan Xing, Ke Yang

Pageof 2

Frequent Collaborators

3 joint publications

Yixiang Zhu

3 joint publications

Junling Li

2 joint publications

Di Ma

2 joint publications

Puyuan Xing